Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Fonar - Where is it going? -- Ignore unavailable to you. Want to Upgrade?

To: William Macko who wrote (10507)	7/17/1998 7:15:00 AM
From: sammy levy	Respond to of 19354

After reading yr post,I must welcome u to the real idiots club.

To: William Macko who wrote (10507)	7/17/1998 1:01:00 PM
From: daveG	Respond to of 19354

Bill you are wrong but no need to apologize. I can see how you might think that. Nice volume today and this little down tic does not feel as bad as I thought it would. As I said before I do not like buying stocks as they are falling, I am more comfortable buying on the way up; this would have worked well for me but I have never gotten enough courage to sell. Fonar is not a trading stock for me it is an investment. I would actually be comfortable owning every single outstanding share. I like the business. This item looks promising but I do not think Fonar is working in this area, but you never know: Magnetic Resonance Test May Give Better Assessment Of Heart Disease Risk -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- RALEIGH, NC -- July 10, 1998 -- A new laboratory test uses radio signals to help detect the unseen risk of heart disease, by giving a clearer reading of cholesterol quality -- surpassing the accuracy of cholesterol blood tests widely in use now. The test uses nuclear magnetic resonance (NMR) technology to measure the sizes of certain lipoproteins - particles that contain and transport cholesterol in the body. A new study reported in this week's edition of the journal Arteriosclerosis, Thrombosis and Vascular Biology , suggests that the new test may be a powerful predictor of heart disease risk and an important weapon in fighting the number one killer of Americans. For years physicians have been perplexed as to why some patients with adverse cholesterol levels never develop heart disease and why some patients with normal cholesterol levels develop coronary artery disease and even die from it. Researchers believe the new test may help to better identify vulnerable patients and better manage patients already being treated for heart disease. "Ultimately, we expect the test will provide a more accurate reading so physicians can better match their therapies to the patient's heart disease risk," said study investigator James Otvos, Ph.D., developer of the test and professor of biochemistry at North Carolina State University. Dr. Otvos also serves as chief scientific officer of LipoMed, company that is commercialising the test as the NMR LipoProfile(TM). The test uses nuclear magnetic resonance technology to assess the levels of 15 different cholesterol types. Lead author David Freedman, Ph.D., senior epidemiologist with the United States Centers for Disease Control and Prevention in Atlanta, and Dr. Otvos observed a striking link between the size and type of lipoproteins and the presence of heart disease among the patient group studied. "It's not cholesterol, per se, that's really important," Otvos said. "Rather, it's the size and type of lipoproteins that count in predicting disease." In a study of 158 men, the individuals with high levels of either small HDL or large VLDL particles were three to four times more likely to have extensive coronary artery disease than other subjects. The 27 men with high levels of both large VLDL and small HDL were 15 times more likely to have extensive heart disease. The findings suggest that large VLDL and small HDL particles may play important roles in the development of heart disease. "It's not enough to know your HDL and LDL numbers any more. Many of us may benefit from adding lipoprotein to our health vocabulary and having a profile that will alert physicians early on to the patient's risk of developing heart disease," 0tvos said. The new test uses NMR technology to measure and record the radio signals emitted by the various lipoproteins in the bloodstream. The radio signals vary by size. A computer analyses the complex signals and a software program provides a graphic representation of the amount and sizes of the various particles. In essence, the test offers physicians an individualized profile of each patient's risk based on their lipoprotein subclasses. Because routine cholesterol measurements may be somewhat off target from measuring the factors that are true indicators of heart disease, many people may be overdiagnosed and others underdiagnosed. Although the NMR equipment is expensive, the tests on a blood sample can be done in minutes. Researchers predict the new test will be comparable in cost to the standard lipid panel. Currently, the NMR technology is used in clinical research to help evaluate and develop medications that may be useful in treating heart disease. -------------------------------------------------------------------------------- More "Top of the News" stories -------------------------------------------------------------------------------- Just type your keywords in the space provided below, then click on the Search button. Enter keywords you wish to find information about: